SMT develops and manufactures cardiac products in India. Its product portfolio includes coronary stents (drug-eluting and bare-metal), renal stents, angioplasty balloon catheters, and other cardiac accessories in India and abroad.
SMT's Product Videos
Compete with SMT?
Ensure that your company and products are accurately represented on our platform.
SMT's Products & Differentiators
Sirolimus Eluting Coronary Stent System
Expert Collections containing SMT
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
SMT is included in 2 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
SMT has filed 1 patent.
Bomb disposal personnel, Waste, Medical equipment, Waste treatment technology, Electrical engineering
Bomb disposal personnel, Waste, Medical equipment, Waste treatment technology, Electrical engineering
Latest SMT News
Nov 23, 2021
As per DelveInsight analysis in Coronary Stents market, increasing prevalence of cardiovascular disorders such as stroke, atherosclerosis, heart attack, the rising geriatric population and growing number of PCI (Percutaneous Coronary Intervention) procedures are some of the key factors, which are expected increase the overall demand of Coronary Stents, thus driving the growth of Coronary Stents market. News provided by Share this article Share this article LAS VEGAS, Nov. 23, 2021 /PRNewswire/ -- DelveInsight's Coronary Stents Market Insights and Forecast report provides the current and forecast Coronary Stents market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Coronary Stents market. Some of the salient features from the Coronary Stents Market report: As per an analysis by DelveInsight, North America is expected to dominate the overall Coronary Stents market during the forecast period. Major pharma players working proactively in the Coronary Stents market include Medtronic, Abbott, Boston Scientific Corporation, Biosensors International Group, Ltd., BIOTRONIK SE & Co. KG, B. Braun Melsungen AG, TERUMO CORPORATION, STENTYS SA, MicroPort Scientific Corporation, Meril Life Sciences Pvt. Ltd., and others. DelveInsight estimates that global Coronary Stents market was valued at USD 8.65 billion in 2020, growing at a CAGR of 7.50% during the forecast period from 2021 to 2026, to reach USD 10.97 billion by 2026. In September 2021, BIOTRONIK received the US Food and Drug Administration (FDA) approval for its Orsiro® Mission bioabsorbable polymer drug-eluting stent system (BP-DES). In August 2020, Boston Scientific Corporation received FDA approval for its SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (Monorail and Over-The-Wire). Interested in knowing how the Coronary Stents Market will be growing by 2026? Click to get a snapshot of Coronary Stents Market Analysis Coronary Stents are expandable tubular metallic devices. These are introduced into the coronary arteries that show stenosis caused by an atherosclerosis disease. It is required during a procedure called percutaneous coronary intervention (PCI) or angioplasty. It is a tiny, expandable metal mesh coil, inserted into the newly opened area of the artery to support the artery from narrowing or closing again. The stent is covered by tissue within 3 to 12 months, depending on if the stent has a medicine coating or not. Stents can aid in the reduction of recurrent blockage or narrowing after an angioplasty procedure. Once the stent is implanted, it will remain in your artery permanently. Types of Coronary Stents includes: Bare metal stents (BMS), Drug-eluting stents (DES), Bioresorbable scaffold system (BRS), and Drug-eluting balloons (DEB). Technical improvements in stent placement and the development of drug-eluting stents (DES) led to greater use of PCI. To pick on the latest highlights related to Coronary Stents, get the snapshot of the key highlights entailed in the Coronary Stents Market report. Geographically, the global Coronary Stents market is studied for North America, Europe, Asia- Pacific, and Rest of the World. In terms of revenue share North America currently leads the global market and is expected that it will remain constant during the forecast period. This domination is observed majorly due to the growing cases of neurologic disorders, rising healthcare expenditure due to strong economy, and presence of well- established healthcare infrastructure. According to DelveInsight estimates, the drug eluting stent is expected to hold the largest market share in 2020 which will remain constant during the forecast period. This is owing to the various advantages of drug eluting stents over bare metal stents and others. Drug eluting stents are more effective in the prevention of restenosis than the use of bare-metal stents, the use of newer-generation drug-eluting stents also reduce the rate of stent thrombosis and myocardial infarction. The launch of new innovative devices will also lead to an increase in the Coronary Stents market growth. For instance, in October 2021, CytoSorbents Corporation announced that the first patient has been enrolled in the Safe and Timely Antithrombotic Removal-Ticagrelor (STAR–T) double-blind, randomized, controlled clinical trial designed to support FDA marketing approval of the DrugSorb-ATR™ Antithrombotic Removal System for intraoperative removal of ticagrelor during cardiothoracic surgery. In October 2020, Biosensors received the CE Mark for BioFreedomUltra, new drug coated coronary stent system with thin strut (84µm) CoCr polymer and Biosensors' Biolimus A9 drug. To know more why North America is leading the market growth in Coronary Stents market, get a snapshot of report Coronary Stents Market Assessment Owing to the rise in the number of cardiovascular disorder cases, growing burden of old age population susceptible to various cardiovascular disorders, shifting preferences towards minimally invasive surgeries, technological advancement in the product line, there will be a rapid growth observed in Coronary Stents market during the forecast period. In addition to that, presence of key manufacturers such as Medtronic, Boston Scientific Corporation, and recent product approvals is also likely to boost the Coronary Stents market. The demand for Coronary Stents is highly affected by the outbreak of the COVID-19 pandemic because of the delay in surgeries needed for the implantation of Coronary Stents. The excessive inflammatory response and hypercoagulable state associated with coronavirus disease (COVID-19) might trigger acute coronary events or stent thrombosis. However, cases of stent thrombosis directly associated with COVID-19 have not been reported. To get a deeper understanding of the driving factors related to the Coronary Stents market, get a snapshot of the Coronary Stents Market Dynamics Study Period: 2018-2026 Key Companies: Medtronic, Abbott, Boston Scientific Corporation, Biosensors International Group, Ltd., BIOTRONIK SE & Co. KG, B. Braun Melsungen AG, TERUMO CORPORATION, STENTYS SA, MicroPort Scientific Corporation, Meril Life Sciences Pvt. Ltd., and others. Coronary Stents Market Segmentation Understand the Competition, Risk Assessment and effective Research and Development approach to take value-based decisions. Related Reports DelveInsight's, "Coronary Stents – Pipeline Insight and Competitive Landscape, 2021," report provides comprehensive insights about 20+ companies and 20+ pipeline devices in Coronary Stents pipeline landscape which include companies like Rontis AG, S3V Vascular Technologies, Sahajanand Medical Technologies Pvt Ltd, Shanghai Bio-heart Biological Technology Co Ltd, Stentys SA, Svelte Medical Systems Inc, Tepha Inc, Terumo Corp, TissueGen Inc, TrendyMED Inc, VasoTech Inc, Viller Scientific LLC, Vornia Biomaterials Ltd, Xenogenics Corporation, Biotronik AG, and others. DelveInsight's 'Vascular Stents - Market Insights, Competitive Landscape and Market Forecast–2026' report delivers an in-depth understanding of Vascular Stents and the historical and forecasted Vascular Stents market trends, market drivers, market barriers and key companies involved such as Medtronic, Abbott Laboratories, Boston Scientific Corporation, BIOTRONIK SE & Co. KG, B. Braun Melsungen AG, Terumo Corporation, STENTYS SA, MicroPort Scientific Corporation, W. L. Gore and Associates, C. R. Bard, Endologix, Lombard Medical Technologies, and others. DelveInsight's 'Urinary Stents -Market Insights, Competitive Landscape and Market Forecast - 2026' report delivers an in-depth understanding of Urinary Stents and the historical and forecasted Urinary Stents market trends, market drivers, market barriers and key companies involved such as Boston Scientific Corporation, B. Braun Holding GmbH & Co. KG, Cook Group Incorporated, C. R. Bard, Coloplast Ltd., Medline Industries, Allium Medical Solutions Ltd, Pnn Medical A/S, Teleflex Incorporated, Olympus Corporation, GBUK Healthcare Ltd, Red Leaf Medical, Dextronix, and several others. DelveInsight's 'Drug-Eluting Stents - Market Insights, Competitive Landscape and Market Forecast–2026' report delivers an in-depth understanding of Drug-Eluting Stents and the historical and forecasted Drug-Eluting Stents market trends, market drivers, market barriers and key companies involved such as Abbott, Braun Melsungen AG, Biosensors International Group, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Terumo Corporation, Medtronic, MicroPort Scientific Corporation, STENTYS SA, Lepu Medical, Cook, Cardinal Health, and others. DelveInsight's 'Biliary Stents Market Insights, Competitive Landscape and Market Forecast-2026' report delivers an in-depth understanding of biliary stents and the historical and forecasted biliary stents market trends, market drivers, market barriers and key companies involved such as Abbot Laboratories, Boston Scientific, Medi-Globe, Bard Medical, Cook India Medical Devices Pvt, Medtronic, Merit Medical Systems, Endocor, InSitu Technologies, and others. DelveInsight's 'Carotid Artery Stent Market - Market Insights, Competitive Landscape and Market Forecast-2026' report delivers an in-depth understanding of Carotid Artery Stent Carotid Artery Stent and the historical and forecasted Carotid Artery Stent market trends, market drivers, market barriers and key companies involved such as Boston Scientific Corporation, Abbott Laboratories, Medtronic plc, Johnson & Johnson, Terumo Corporation, MicroPort Scientific Corporation, W. L. Gore & Associates, BIOTRONIK SE & Co. KG, InspireMD, Contego Medical, Impulse Dynamics, and others. Browse Through Our Blog Posts Evaluating the Role of Digital Therapeutics as an Alternative to Conventional Therapies for Depression Medical Devices Market Blooms as the Key MedTech Companies Continue to Bring-In Innovation MedTech Industry Roars Back as FDA Approvals Soar Contact Us
SMT Web Traffic
SMT Frequently Asked Questions (FAQ)
When was SMT founded?
SMT was founded in 1998.
Where is SMT's headquarters?
SMT's headquarters is located at Sahajanand Estate, Wakhariawadi, Near Dabholi, Surat.
What is SMT's latest funding round?
SMT's latest funding round is Private Equity - II.
How much did SMT raise?
SMT raised a total of $61.06M.
Who are the investors of SMT?
Investors of SMT include Morgan Stanley Global Private Equity and Samara Capital.
Who are SMT's competitors?
Competitors of SMT include Bioheart and 1 more.
What products does SMT offer?
SMT's products include Supraflex Cruz and 1 more.
Compare SMT to Competitors
Quasar specializes in the manufacturing of products for the medical device market, and focuses on minimally invasive devices and disposables.
Translumina is a global Interventional cardiovascular devices company. Translumina is a fully integrated product development and manufacturing company with manufacturing facilities in Germany and India. The company commercializes products in over 50 countries globally through 2 distinct business entities, International and India.
Acorai develops a device for heart failure management through non-invasive intracardiac pressure monitoring (ICPM) to help reduce hospitalizations and readmissions. The Acorai Heart Monitor can monitor intracardiac pressures non-invasively through a machine learning analysis of pressure dynamics in acoustics, vibratory, and waveform data. The company was founded in 2019 and is based in Helsingborg, Sweden.
General Prognostics is a developer of bloodless blood tests for remote chronic disease management. The company was founded in 2020 and is based in Boston, Massachusetts.
Ceryx Medical develops a bioelectronic technology that could change the way diseases such as heart failure are treated. Employing biomimetic design principles and patented electronics, Ceryx has created a range of smart bioelectronic medical devices that speak the same language as the human body. The company was founded in 2016 and is based in Cardiff, Wales.
Bodyport is a data-driven virtual clinic for the prevention and management of heart disease. The firm provides advanced cardiac monitoring and connected care in every home.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.